Skip to content
Amplo Biotechnology logo — Pioneering AAV therapies for neuromuscular junction diseases...

Amplo Biotechnology

Pioneering AAV therapies for neuromuscular junction diseases, targeting congenital myasthenic syndromes with innovative solutions.

Founded 2019 3 employees Grant Total: $2.24M Biotechnology, Health Care +1

General Information

Company Name Amplo Biotechnology
Founded Year 2019
Employees 3
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Amplo Biotechnology. To contact Amplo Biotechnology, visit amplobiotechnology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Amplo Biotechnology compare?

A PDF of Amplo Biotechnology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Amplo Biotechnology soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Amplo Biotechnology

Amplo Biotechnology is a biotech startup founded in 2019, with a mission to develop innovative Adeno-Associated Viral (AAV) therapies for neuromuscular junction diseases, particularly focusing on congenital myasthenic syndromes. The firm's flagship program, AAV-Dok7, which stems from the research conducted by Professor Yuji Yamanashi's team at the Institute of Medical Science, University of Tokyo, has the potential to address multiple rare and severe diseases. The company has received a grant investment from NIAMS as of 29th May 2023. Amplo Biotechnology operates within the biotechnology, health care, and health and wellness industries, aiming to pioneer AAV therapies for these critical health challenges.

Business keywords: AAV therapies, neuromuscular junction diseases, congenital myasthenic syndromes, rare diseases, paralysis treatment, breathing difficulties, swallowing difficulties, genetic diseases, medical research, University of Tokyo, Professor Yuji Yamanashi, Institute of Medical Science, rare disease treatments, innovative medical solutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
NIAMS
29 May 2023
Grant Undisclosed 1
National Institutes of Health
06 Oct 2021
Seed Round $2.24M 3
Casdin Capital, BioBrit +1
01 Oct 2021

Amplo Biotechnology Alternatives & Competitors

View All Alternatives
Amplo Biotechnology vs
Axovia Therapeutics
Axovia Therapeutics United Kingdom

Driving gene therapy breakthroughs to develop transformative AAV treatments for patients with ciliop...

7 employees
Biopharma, Biotechnology
Amplo Biotechnology vs
Yaqrit
Yaqrit United Kingdom

The Liver Disease Company

Convertible Note
14 employees
Biotechnology, Health Care
Amplo Biotechnology vs
Lexeo Therapeutics
Lexeo Therapeutics United States

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's d...

Post-IPO Equity
97 employees
Biotechnology, Health and Wellness

FAQ About Amplo Biotechnology

Pioneering AAV therapies for neuromuscular junction diseases, targeting congenital myasthenic syndromes with innovative solutions.
Amplo Biotechnology was founded in 2019.
Amplo Biotechnology operates in Biotechnology, Health Care and Health and Wellness. Its work centres on AAV therapies, neuromuscular junction diseases, congenital myasthenic syndromes and rare diseases.
Amplo Biotechnology has approximately 3 employees.
Amplo Biotechnology has completed 3 funding rounds, raising a total of $2.24M. The latest funding stage is Grant.
Top alternatives and competitors to Amplo Biotechnology include Axovia Therapeutics, Yaqrit, Lexeo Therapeutics, Apertura Gene Therapy, Genecure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amplo Biotechnology and Axovia Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Amplo Biotechnology, https://bouncewatch.com/company/amplo-biotechnology, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout